Skip to main content

Peer Review reports

From: miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer

Original Submission
30 Jan 2012 Submitted Original manuscript
23 Feb 2012 Reviewed Reviewer Report - Satoshi Anai
6 Mar 2012 Reviewed Reviewer Report - Evan Gomes
14 Mar 2012 Author responded Author comments - Sabrina Reis
Resubmission - Version 2
14 Mar 2012 Submitted Manuscript version 2
19 Mar 2012 Author responded Author comments - Sabrina Reis
29 Mar 2012 Reviewed Reviewer Report - Evan Gomes
Resubmission - Version 3
19 Mar 2012 Submitted Manuscript version 3
Publishing
4 May 2012 Editorially accepted
29 May 2012 Article published 10.1186/1471-2490-12-14

You can find further information about peer review here.

Back to article page